Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.
about
Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic reviewPopulation-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysisEvaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort StudyUnderstanding Toxoplasmosis in the United States Through "Large Data" AnalysesDevelopment and initial feedback about a human papillomavirus (HPV) vaccine comic book for adolescents.Recurrent and Sustained Viral Infections in Primary Immunodeficiencies.Sexually transmitted diseases treatment guidelines, 2015.Correlates of human papillomavirus vaccine coverage: a state-level analysisHigh-risk human papillomavirus infection in the prediction of poor treatment response and disease recurrence in patients with vulvovaginal condyloma.Trends in Genital Warts in the Era of Human Papillomavirus Vaccination.The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.Impact of HPV vaccination on anogenital warts and respiratory papillomatosisConcept Analysis: Health-Promoting Behaviors Related to Human Papilloma Virus (HPV) Infection.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data.Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.CDC grand rounds: Reducing the burden of HPV-associated cancer and disease.The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation.Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.Monitoring the impact of HPV vaccine in males-Considerations and challenges.Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003-2014.Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies
P2860
Q28081927-86E228F8-F9B1-4A26-A9DA-021992D93AD5Q28084924-8926F30D-C66F-4062-B015-0196EF5FBC68Q28647510-260D397E-D0AA-44F7-9A8E-D573F49D2849Q31111181-1E0934F3-249D-4A18-B518-2D267E684029Q33645571-C1D7531E-82B7-48AE-923D-900BA429AE1DQ33809611-07C11C3B-045F-466E-99E8-B394A90159C2Q34479272-F0B31A03-8EC7-4CDF-972D-38D0A3C2C355Q34970962-18A5BC95-B5AA-42A8-8A35-A6285DDCC7C4Q35805354-E72A7B3F-6810-49D1-9808-A3D6A961C76BQ36289231-74D4D3DD-B2DB-4FB2-9CA5-FD32D13D728AQ37135272-4B8F1DAB-4A94-4E65-B329-397C33B63D58Q37284313-F9AE02A2-1921-4C90-A796-CB1B1CA866E1Q38220738-30064CE4-6339-44AA-83AF-FCBAE95FFE21Q38229304-EC4C4494-EE33-4B5D-87C8-2CFCD6ED7678Q38399052-FD191FBF-64DF-465F-9E01-6A8B572AB1E6Q38648167-C4AB18E1-E6C8-43FD-AE02-4C095442526EQ38804622-B86B2E7D-AEBC-4BC6-8F3E-17EE05A8142BQ40215017-CF514656-CC63-4A57-BE80-028A29C46876Q41933605-E9528138-3C29-4D26-A046-9093270F9592Q42240209-22D21A8D-D111-4211-A79D-43AAD0674576Q47625999-BE65A691-351B-4447-BB74-5B70751414B3Q49206271-D88B1FC3-665F-464E-B8DE-00D7C29C7BABQ50091385-13FC13B8-C665-41ED-BC80-6F52C151A072Q54258215-360536A7-73BB-49AF-AC94-B758BC658F2EQ54313120-9741AE7B-0D65-4B75-B654-B4074F378549Q58548093-DB09291F-F394-41C4-910F-B783E7841DBF
P2860
Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prevalence of anogenital warts ...... an papillomavirus vaccination.
@en
Prevalence of anogenital warts ...... an papillomavirus vaccination.
@nl
type
label
Prevalence of anogenital warts ...... an papillomavirus vaccination.
@en
Prevalence of anogenital warts ...... an papillomavirus vaccination.
@nl
prefLabel
Prevalence of anogenital warts ...... an papillomavirus vaccination.
@en
Prevalence of anogenital warts ...... an papillomavirus vaccination.
@nl
P2093
P2860
P356
P1476
Prevalence of anogenital warts ...... an papillomavirus vaccination.
@en
P2093
Elaine W Flagg
Hillard Weinstock
Robert Schwartz
P2860
P304
P356
10.2105/AJPH.2012.301182
P407
P577
2013-06-13T00:00:00Z